{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:07:25Z","timestamp":1779268045662,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["KAKENHI 23K06077"],"award-info":[{"award-number":["KAKENHI 23K06077"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04905-w","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:22:30Z","timestamp":1779265350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antitumor efficacy and reduced systemic toxicity of palmitic acid-modified pirarubicin nanoparticles in mice"],"prefix":"10.1007","volume":"96","author":[{"given":"Kenji","family":"Tsukigawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kindness Lomotey","family":"Commey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"4905_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.7164\/antibiotics.36.312","volume":"36","author":"S Kunimoto","year":"1983","unstructured":"Kunimoto S, Miura K, Takahashi Y et al (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4\u2019-O-tetrahydropyranyladriamycin. J Antibiot 36:312\u2013317. https:\/\/doi.org\/10.7164\/antibiotics.36.312","journal-title":"J Antibiot"},{"key":"4905_CR2","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.7164\/antibiotics.37.1697","volume":"37","author":"S Kunimoto","year":"1984","unstructured":"Kunimoto S, Miura K, Umezawa K et al (1984) Cellular uptake and efflux and cytostatic activity of 4\u2019-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. J Antibiot 37:1697\u20131702. https:\/\/doi.org\/10.7164\/antibiotics.37.1697","journal-title":"J Antibiot"},{"key":"4905_CR3","first-page":"1462","volume":"42","author":"T Tsuruo","year":"1982","unstructured":"Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) 4\u2019-O-tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 42:1462\u20131467","journal-title":"Cancer Res"},{"key":"4905_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1203\/00006450-200202000-00021","volume":"51","author":"E Koh","year":"2002","unstructured":"Koh E, Ueda Y, Nakamura T et al (2002) Apoptosis in young rats with adriamycin-induced cardiomyopathy\u2014comparison with pirarubicin, a new anthracycline derivative. Pediatr Res 51:256\u2013259","journal-title":"Pediatr Res"},{"key":"4905_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/cas.12592","volume":"106","author":"K Tsukigawa","year":"2015","unstructured":"Tsukigawa K, Liao L, Nakamura H et al (2015) Synthesis and therapeutic effect of styrene-maleic acid copolymer-conjugated pirarubicin. Cancer Sci 106:270\u2013278. https:\/\/doi.org\/10.1111\/cas.12592","journal-title":"Cancer Sci"},{"key":"4905_CR6","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1021\/acs.molpharmaceut.5b00536","volume":"12","author":"X Yi","year":"2015","unstructured":"Yi X, Lian X, Dong J et al (2015) Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers. Mol Pharm 12:4085\u20134098. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00536","journal-title":"Mol Pharm"},{"key":"4905_CR7","doi-asserted-by":"publisher","first-page":"157818","DOI":"10.1016\/j.phymed.2026.157818","volume":"151","author":"Q Li","year":"2026","unstructured":"Li Q, Qin M, Liu P, Liu M (2026) Rutin alleviates pirarubicin-induced cardiotoxicity and enhances chemosensitivity in breast cancer. Phytomedicine 151:157818. https:\/\/doi.org\/10.1016\/j.phymed.2026.157818","journal-title":"Phytomedicine"},{"key":"4905_CR8","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","volume":"95","author":"SK Hobbs","year":"1998","unstructured":"Hobbs SK, Monsky WL, Yuan F et al (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 95:4607\u20134612","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4905_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","volume":"65","author":"H Maeda","year":"2013","unstructured":"Maeda H, Nakamura H, Fang J (2013) The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65:71\u201379. https:\/\/doi.org\/10.1016\/j.addr.2012.10.002","journal-title":"Adv Drug Deliv Rev"},{"key":"4905_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01536-y","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M et al (2023) Nanomedicine in cancer therapy. Signal Transduct Target Therapy. https:\/\/doi.org\/10.1038\/s41392-023-01536-y. 8:","journal-title":"Signal Transduct Target Therapy"},{"key":"4905_CR11","doi-asserted-by":"publisher","first-page":"114449","DOI":"10.1016\/j.addr.2022.114449","volume":"188","author":"Y Zi","year":"2022","unstructured":"Zi Y, Yang K, He J et al (2022) Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Adv Drug Deliv Rev 188:114449. https:\/\/doi.org\/10.1016\/j.addr.2022.114449","journal-title":"Adv Drug Deliv Rev"},{"key":"4905_CR12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.jconrel.2013.09.019","volume":"172","author":"AO Elzoghby","year":"2013","unstructured":"Elzoghby AO (2013) Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release 172:1075\u20131091. https:\/\/doi.org\/10.1016\/j.jconrel.2013.09.019","journal-title":"J Control Release"},{"key":"4905_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-65773-9","volume":"10","author":"T Huang","year":"2020","unstructured":"Huang T, Wang Y, Shen Y et al (2020) Preparation of high drug-loading celastrol nanosuspensions and their anti-breast cancer activities in vitro and in vivo. Sci Rep 10:1\u20139. https:\/\/doi.org\/10.1038\/s41598-020-65773-9","journal-title":"Sci Rep"},{"key":"4905_CR14","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2217\/nnm.15.73","volume":"10","author":"Y Lu","year":"2015","unstructured":"Lu Y, Chen Y, Gemeinhart RA et al (2015) Developing nanocrystals for cancer treatment. Nanomedicine 10:2537\u20132552. https:\/\/doi.org\/10.2217\/nnm.15.73","journal-title":"Nanomedicine"},{"key":"4905_CR15","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s11095-009-9855-9","volume":"26","author":"W Jiskoot","year":"2009","unstructured":"Jiskoot W, Van Schie RMF, Carstens MG, Schellekens H (2009) Immunological risk of injectable drug delivery systems. Pharm Res 26:1303\u20131314. https:\/\/doi.org\/10.1007\/s11095-009-9855-9","journal-title":"Pharm Res"},{"key":"4905_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.addr.2010.09.001","volume":"63","author":"H Hatakeyama","year":"2011","unstructured":"Hatakeyama H, Akita H, Harashima H (2011) A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63:152\u2013160. https:\/\/doi.org\/10.1016\/j.addr.2010.09.001","journal-title":"Adv Drug Deliv Rev"},{"key":"4905_CR17","doi-asserted-by":"publisher","first-page":"115239","DOI":"10.1016\/j.addr.2024.115239","volume":"207","author":"J Liu","year":"2024","unstructured":"Liu J, Cabral H, Mi P (2024) Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release. Adv Drug Deliv Rev 207:115239. https:\/\/doi.org\/10.1016\/j.addr.2024.115239","journal-title":"Adv Drug Deliv Rev"},{"key":"4905_CR18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12951-022-01644-x","volume":"20","author":"MK Shim","year":"2022","unstructured":"Shim MK, Yang S, Park J et al (2022) Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity. J Nanobiotechnol 20:436. https:\/\/doi.org\/10.1186\/s12951-022-01644-x","journal-title":"J Nanobiotechnol"},{"key":"4905_CR19","doi-asserted-by":"publisher","first-page":"15256","DOI":"10.1039\/d4nr01763c","volume":"16","author":"K Tanita","year":"2024","unstructured":"Tanita K, Koseki Y, Kumar S et al (2024) Carrier-free nano-prodrugs for minimally invasive cancer therapy. Nanoscale 16:15256\u201315264. https:\/\/doi.org\/10.1039\/d4nr01763c","journal-title":"Nanoscale"},{"key":"4905_CR20","doi-asserted-by":"publisher","first-page":"23827","DOI":"10.1021\/acsnano.4c09027","volume":"18","author":"F Fang","year":"2024","unstructured":"Fang F, Chen X (2024) Carrier-Free Nanodrugs: From Bench to Bedside. ACS Nano 18:23827\u201323841. https:\/\/doi.org\/10.1021\/acsnano.4c09027","journal-title":"ACS Nano"},{"key":"4905_CR21","doi-asserted-by":"publisher","first-page":"117258","DOI":"10.1016\/j.biopha.2024.117258","volume":"178","author":"J An","year":"2024","unstructured":"An J, Zhang Z, Zhang J et al (2024) Research progress in tumor therapy of carrier-free nanodrug. Biomed Pharmacother 178:117258. https:\/\/doi.org\/10.1016\/j.biopha.2024.117258","journal-title":"Biomed Pharmacother"},{"key":"4905_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1248\/cpb.c23-00701","volume":"72","author":"T Hasegawa","year":"2024","unstructured":"Hasegawa T, Tsukigawa K, Commey K et al (2024) Preparation and in Vitro Characterization of Fatty-Acid Modified Pirarubicin Nanosuspensions Stabilized by Albumin. Chem Pharm Bull 72:21\u201327. https:\/\/doi.org\/10.1248\/cpb.c23-00701","journal-title":"Chem Pharm Bull"},{"key":"4905_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jcis.2016.10.041","volume":"487","author":"J Liu","year":"2017","unstructured":"Liu J, Zhao D, He W et al (2017) Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy. J Colloid Interface Sci 487:239\u2013249. https:\/\/doi.org\/10.1016\/j.jcis.2016.10.041","journal-title":"J Colloid Interface Sci"},{"key":"4905_CR24","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1021\/acs.bioconjchem.0c00564","volume":"31","author":"CE De Castro","year":"2020","unstructured":"De Castro CE, Panico K, Stangherlin LM et al (2020) The Protein Corona Conundrum: Exploring the Advantages and Drawbacks of its Presence around Amphiphilic Nanoparticles. Bioconjug Chem 31:2638\u20132647. https:\/\/doi.org\/10.1021\/acs.bioconjchem.0c00564","journal-title":"Bioconjug Chem"},{"key":"4905_CR25","doi-asserted-by":"publisher","unstructured":"Okamoto Y, Taguchi K, Yamasaki K et al (2018) Albumin-Encapsulated Liposomes: A Novel Drug Delivery Carrier With Hydrophobic Drugs Encapsulated in the Inner Aqueous Core. J Pharm Sci 107. https:\/\/doi.org\/10.1016\/j.xphs.2017.08.003","DOI":"10.1016\/j.xphs.2017.08.003"},{"key":"4905_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM et al (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery 20:101\u2013124. https:\/\/doi.org\/10.1038\/s41573-020-0090-8","journal-title":"Nat Rev Drug Discovery"},{"key":"4905_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijbiomac.2015.08.006","volume":"81","author":"N Sahoo","year":"2015","unstructured":"Sahoo N, Sahoo RK, Biswas N et al (2015) Recent advancement of gelatin nanoparticles in drug and vaccine delivery. Int J Biol Macromol 81:317\u2013331. https:\/\/doi.org\/10.1016\/j.ijbiomac.2015.08.006","journal-title":"Int J Biol Macromol"},{"key":"4905_CR28","doi-asserted-by":"publisher","first-page":"106425","DOI":"10.1016\/j.ejps.2023.106425","volume":"185","author":"Y Ma","year":"2023","unstructured":"Ma Y, Cong Z, Gao P, Wang Y (2023) Nanosuspensions technology as a master key for nature products drug delivery and In vivo fate. Eur J Pharm Sci 185:106425. https:\/\/doi.org\/10.1016\/j.ejps.2023.106425","journal-title":"Eur J Pharm Sci"},{"key":"4905_CR29","doi-asserted-by":"publisher","first-page":"20799","DOI":"10.1039\/D4RA01955E","volume":"14","author":"D Fu","year":"2024","unstructured":"Fu D, Zhong L, Xu J et al (2024) Hydrazone-functionalized nanoscale covalent organic frameworks as a nanocarrier for pH-responsive drug delivery enhanced anticancer activity. RSC Adv 14:20799\u201320808. https:\/\/doi.org\/10.1039\/D4RA01955E","journal-title":"RSC Adv"},{"key":"4905_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12951-022-01257-4","volume":"20","author":"L Huang","year":"2022","unstructured":"Huang L, Yang J, Wang T et al (2022) Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery. J Nanobiotechnol 20:49. https:\/\/doi.org\/10.1186\/s12951-022-01257-4","journal-title":"J Nanobiotechnol"},{"key":"4905_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s43246-026-01073-5","volume":"7","author":"J Menge","year":"2026","unstructured":"Menge J, Yang C, Weitz DA, Jahnke K (2026) Engineering the biophysical properties of lipid nanostructures for drug delivery. Commun Mater 7:25. https:\/\/doi.org\/10.1038\/s43246-026-01073-5","journal-title":"Commun Mater"},{"key":"4905_CR32","doi-asserted-by":"publisher","first-page":"16421","DOI":"10.1021\/acsami.9b05599","volume":"11","author":"Z Pan","year":"2019","unstructured":"Pan Z, He X, Song N et al (2019) Albumin-Modified Cationic Nanocarriers to Potentially Create a New Platform for Drug Delivery Systems. ACS Appl Mater Interfaces 11:16421\u201316429. https:\/\/doi.org\/10.1021\/acsami.9b05599","journal-title":"ACS Appl Mater Interfaces"},{"key":"4905_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1517\/17425247.2010.485983","volume":"7","author":"E Bilensoy","year":"2010","unstructured":"Bilensoy E (2010) Cationic nanoparticles for cancer therapy. Expert Opin Drug Deliv 7:795\u2013809. https:\/\/doi.org\/10.1517\/17425247.2010.485983","journal-title":"Expert Opin Drug Deliv"},{"key":"4905_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep10649","volume":"5","author":"G Fullstone","year":"2015","unstructured":"Fullstone G, Wood J, Holcombe M, Battaglia G (2015) Modelling the transport of nanoparticles under blood flow using an agent-based approach. Sci Rep 5:1\u201313. https:\/\/doi.org\/10.1038\/srep10649","journal-title":"Sci Rep"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04905-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04905-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04905-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:22:30Z","timestamp":1779265350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04905-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4905"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04905-w","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving animal experiments were in accordance with the ethical standards of the Animal Care and Use Committee of Sojo University. This article does not contain any studies with human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"52"}}